NRG-GY036: A Phase III Trial of One vs Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
- Title
- A Phase III Trial of One vs Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
- Principal Investigator
- Pfaendler, Krista
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Gynecologic Cancers
- Participating Institutions
- Berkeley Medical Center
- Camden Clark Medical Center
- Mary Babb Randolph Cancer Center
- Contacts
- Valli White, RN
- Research Nurse
- Phone: +1 304-264-1220
- Email: valli.white@wvumedicine.org
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org
- Jill Stone, LPN
- Research Specialist
- Phone: +1 304-634-4417
- Email: jill.stone@hsc.wvu.edu